{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,31]],"date-time":"2024-07-31T00:33:21Z","timestamp":1722386001120},"reference-count":29,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,7,30]]},"DOI":"10.7759\/cureus.65716","type":"journal-article","created":{"date-parts":[[2024,7,30]],"date-time":"2024-07-30T07:17:07Z","timestamp":1722323827000},"source":"Crossref","is-referenced-by-count":0,"title":["Chronic Cough as the First Clinical Sign of Fabry Disease: A Case Report"],"prefix":"10.7759","author":[{"given":"Katarzyna","family":"Muras-Szwedziak","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kacper","family":"Mazurkiewicz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leon","family":"Pawlik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Krzysztof","family":"Kaczmarek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1007\/s00441-017-2609-9","article-title":"Pathomechanisms of renal Fabry disease","volume":"369","author":"Eikrem \u00d8","year":"2017","unstructured":"Eikrem \u00d8, Skrunes R, T\u00f8ndel C, Leh S, Houge G, Svarstad E, Marti HP. Pathomechanisms of renal Fabry disease. Cell Tissue Res. 2017, 369:53-62. 10.1007\/s00441-017-2609-9","journal-title":"Cell Tissue Res"},{"key":"ref2","article-title":"A review of Fabry disease","volume":"23","author":"Chan B","year":"2018","unstructured":"Chan B, Adam DN. A review of Fabry disease. Skin Ther Lett. 2018, 23:4-6.","journal-title":"Skin Ther Lett"},{"key":"ref3","article-title":"Fabry disease","author":"Bokhari SRA","year":"2024","unstructured":"Bokhari SRA, Zulfiqar H, Hariz A. Fabry disease. StatPearls [Internet]. StatPearls Publishing, Treasure Island, FL; 2024."},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2014.06.029","article-title":"Fabry's disease","volume":"344","author":"El-Abassi R","year":"2014","unstructured":"El-Abassi R, Singhal D, England JD. Fabry's disease. J Neurol Sci. 2014, 344:5-19. 10.1016\/j.jns.2014.06.029","journal-title":"J Neurol Sci"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)61589-5","article-title":"Fabry\u2019s disease","volume":"372","author":"Zarate YA","year":"2008","unstructured":"Zarate YA, Hopkin RJ. Fabry\u2019s disease. Lancet Lond Engl. 2008, 372:1427-35. 10.1016\/S0140-6736(08)61589-5","journal-title":"Lancet Lond Engl"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgme.2018.02.014","article-title":"Fabry disease revisited: management and treatment recommendations for adult patients","volume":"123","author":"Ortiz A","year":"2018","unstructured":"Ortiz A, Germain DP, Desnick RJ, et al.. Fabry disease revisited: management and treatment recommendations for adult patients. Mol Genet Metab. 2018, 123:416-27. 10.1016\/j.ymgme.2018.02.014","journal-title":"Mol Genet Metab"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1136\/heart.89.8.819","article-title":"Fabry disease","volume":"89","author":"Nagueh SF","year":"2003","unstructured":"Nagueh SF. Fabry disease. Heart. 2003, 89:819-20. 10.1136\/heart.89.8.819","journal-title":"Heart"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2012.03.020","article-title":"Overlooked signs and symptoms: lung","volume":"34","author":"Linhart A","year":"2012","unstructured":"Linhart A, Magage S, Dostalov\u011b G, Susa Z. Overlooked signs and symptoms: lung. Clin Ther. 2012, 34:E11-2. 10.1016\/j.clinthera.2012.03.020","journal-title":"Clin Ther"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejim.2013.05.003","article-title":"Pulmonary involvement in Fabry disease: overview and perspectives","volume":"24","author":"Franzen D","year":"2013","unstructured":"Franzen D, Krayenbuehl PA, Lidove O, Aubert JD, Barbey F. Pulmonary involvement in Fabry disease: overview and perspectives. Eur J Intern Med. 2013, 24:707-13. 10.1016\/j.ejim.2013.05.003","journal-title":"Eur J Intern Med"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20020327","article-title":"Molecular pathways and respiratory involvement in lysosomal storage diseases","volume":"20","author":"Faverio P","year":"2019","unstructured":"Faverio P, Stainer A, De Giacomi F, et al.. Molecular pathways and respiratory involvement in lysosomal storage diseases. Int J Mol Sci. 2019, 20:327. 10.3390\/ijms20020327","journal-title":"Int J Mol Sci"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1136\/thorax.55.8.720","article-title":"Induced sputum examination: diagnosis of pulmonary involvement in Fabry's disease","volume":"55","author":"Kelly MM","year":"2000","unstructured":"Kelly MM, Leigh R, McKenzie R, Kamada D, Ramsdale EH, Hargreave FE. Induced sputum examination: diagnosis of pulmonary involvement in Fabry's disease. Thorax. 2000, 55:720-1. 10.1136\/thorax.55.8.720","journal-title":"Thorax"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1007\/s10545-008-0930-x","article-title":"Enzyme replacement therapy stabilizes obstructive pulmonary Fabry disease associated with respiratory globotriaosylceramide storage","volume":"31","author":"Wang RY","year":"2008","unstructured":"Wang RY, Abe JT, Cohen AH, Wilcox WR. Enzyme replacement therapy stabilizes obstructive pulmonary Fabry disease associated with respiratory globotriaosylceramide storage. J Inherit Metab Dis. 2008, 31:S369-74. 10.1007\/s10545-008-0930-x","journal-title":"J Inherit Metab Dis"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2559.1991.tb01510.x","article-title":"Pulmonary vasculature in Fabry's disease","volume":"19","author":"Smith P","year":"1991","unstructured":"Smith P, Heath D, Rodgers B, Helliwell T. Pulmonary vasculature in Fabry's disease. Histopathology. 1991, 19:567-9. 10.1111\/j.1365-2559.1991.tb01510.x","journal-title":"Histopathology"},{"key":"ref14","article-title":"Fabry Disease: Perspectives From 5 Years of FOS","author":"Mehta A","year":"2006","unstructured":"Mehta A, Beck M, Sunder-Plassmann G. Fabry Disease: Perspectives From 5 Years of FOS. Oxford PharmaGenesis, Oxford; 2006."},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1111\/cge.13546","article-title":"Consensus recommendations for diagnosis, management and treatment of Fabry disease in paediatric patients","volume":"96","author":"Germain DP","year":"2019","unstructured":"Germain DP, Fouilhoux A, Decramer S, et al.. Consensus recommendations for diagnosis, management and treatment of Fabry disease in paediatric patients. Clin Genet. 2019, 96:107-17. 10.1111\/cge.13546","journal-title":"Clin Genet"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(04)16254-5","article-title":"Recurrent acroparaesthesia during febrile infections","volume":"363","author":"Bodamer OA","year":"2004","unstructured":"Bodamer OA, Ratschmann R, Paschke E, Voigtl\u00e4nder T, Stockler-Ipsiroglu S. Recurrent acroparaesthesia during febrile infections. Lancet. 2004, 363:1698. 10.1016\/S0140-6736(04)16254-5","journal-title":"Lancet"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.3390\/cells10061532","article-title":"Fabry cardiomyopathy: current practice and future directions","volume":"10","author":"Yim J","year":"2021","unstructured":"Yim J, Yau O, Yeung DF, Tsang TS. Fabry cardiomyopathy: current practice and future directions. Cells. 2021, 10:1532. 10.3390\/cells10061532","journal-title":"Cells"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjms.2020.07.011","article-title":"When and how to diagnose Fabry disease in clinical practice","volume":"360","author":"Michaud M","year":"2020","unstructured":"Michaud M, Mauhin W, Belmatoug N, et al.. When and how to diagnose Fabry disease in clinical practice. Am J Med Sci. 2020, 360:641-9. 10.1016\/j.amjms.2020.07.011","journal-title":"Am J Med Sci"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2018-eular.2757","article-title":"SAT0627 Fabry disease: diagnostic errors in rheumatology practice","volume":"77","author":"Moiseev S","year":"2018","unstructured":"Moiseev S, Novikov P, Bulanov N, Karovaikina E, Moiseev A, Fomin V. SAT0627 Fabry disease: diagnostic errors in rheumatology practice. Ann Rheum Dis. 2018, 77:1164-5. 10.1136\/annrheumdis-2018-eular.2757","journal-title":"Ann Rheum Dis"},{"key":"ref20","article-title":"Fabry's disease: case series and review of literature","volume":"6","author":"Wani MM","year":"2016","unstructured":"Wani MM, Khan I, Bhat RA, Ahmad M. Fabry's disease: case series and review of literature. Ann Med Health Sci Res. 2016, 6:193-7.","journal-title":"Ann Med Health Sci Res"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1111\/crj.13150","article-title":"Pulmonary involvement in selected lysosomal storage diseases and the impact of enzyme replacement therapy: a state-of-the art review","volume":"14","author":"Jezela-Stanek A","year":"2020","unstructured":"Jezela-Stanek A, Chorostowska-Wynimko J, Tylki-Szyma\u0144ska A. Pulmonary involvement in selected lysosomal storage diseases and the impact of enzyme replacement therapy: a state-of-the art review. Clin Respir J. 2020, 14:422-9. 10.1111\/crj.13150","journal-title":"Clin Respir J"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0180437","article-title":"Long-term follow-up of pulmonary function in Fabry disease: a bi-center observational study","volume":"12","author":"Franzen DP","year":"2017","unstructured":"Franzen DP, Nowak A, Haile SR, et al.. Long-term follow-up of pulmonary function in Fabry disease: a bi-center observational study. PLoS One. 2017, 12:e0180437. 10.1371\/journal.pone.0180437","journal-title":"PLoS One"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgme.2017.09.004","article-title":"Contribution of inflammatory pathways to Fabry disease pathogenesis","volume":"122","author":"Rozenfeld P","year":"2017","unstructured":"Rozenfeld P, Feriozzi S. Contribution of inflammatory pathways to Fabry disease pathogenesis. Mol Genet Metab. 2017, 122:19-27. 10.1016\/j.ymgme.2017.09.004","journal-title":"Mol Genet Metab"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.3402\/ecrj.v2.26721","article-title":"Fabry disease, respiratory symptoms, and airway limitation - a systematic review","volume":"2","author":"Svensson CK","year":"2015","unstructured":"Svensson CK, Feldt-Rasmussen U, Backer V. Fabry disease, respiratory symptoms, and airway limitation - a systematic review. Eur Clin Respir J. 2015, 2:26721. 10.3402\/ecrj.v2.26721","journal-title":"Eur Clin Respir J"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2012030316","article-title":"Agalsidase benefits renal histology in young patients with Fabry disease","volume":"24","author":"T\u00f8ndel C","year":"2013","unstructured":"T\u00f8ndel C, Bostad L, Larsen KK, Hirth A, Vikse BE, Houge G, Svarstad E. Agalsidase benefits renal histology in young patients with Fabry disease. J Am Soc Nephrol. 2013, 24:137-48. 10.1681\/ASN.2012030316","journal-title":"J Am Soc Nephrol"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-021-01486-1","article-title":"Fabry disease: the current treatment landscape","volume":"81","author":"Lenders M","year":"2021","unstructured":"Lenders M, Brand E. Fabry disease: the current treatment landscape. Drugs. 2021, 81:635-45. 10.1007\/s40265-021-01486-1","journal-title":"Drugs"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.3390\/medicina56060284","article-title":"Kidney transplant in Fabry disease: a revision of the literature","volume":"56","author":"Capelli I","year":"2020","unstructured":"Capelli I, Aiello V, Gasperoni L, et al.. Kidney transplant in Fabry disease: a revision of the literature. Medicina (Kaunas). 2020, 56:284. 10.3390\/medicina56060284","journal-title":"Medicina (Kaunas)"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1136\/bmjresp-2018-000277","article-title":"Pulmonary involvement in Fabry disease: effect of plasma globotriaosylsphingosine and time to initiation of enzyme replacement therapy","volume":"5","author":"Franzen D","year":"2018","unstructured":"Franzen D, Haile SR, Kasper DC, Mechtler TP, Flammer AJ, Krayenb\u00fchl PA, Nowak A. Pulmonary involvement in Fabry disease: effect of plasma globotriaosylsphingosine and time to initiation of enzyme replacement therapy. BMJ Open Respir Res. 2018, 5:e000277. 10.1136\/bmjresp-2018-000277","journal-title":"BMJ Open Respir Res"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1111\/crj.12446","article-title":"Long time enzyme replacement therapy stabilizes obstructive lung disease and alters peripheral immune cell subsets in Fabry patients","volume":"11","author":"Odler B","year":"2017","unstructured":"Odler B, Cseh \u00c1, Constantin T, et al.. Long time enzyme replacement therapy stabilizes obstructive lung disease and alters peripheral immune cell subsets in Fabry patients. Clin Respir J. 2017, 11:942-50. 10.1111\/crj.12446","journal-title":"Clin Respir J"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/275751-chronic-cough-as-the-first-clinical-sign-of-fabry-disease-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,30]],"date-time":"2024-07-30T07:17:13Z","timestamp":1722323833000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/275751-chronic-cough-as-the-first-clinical-sign-of-fabry-disease-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,30]]},"references-count":29,"URL":"https:\/\/doi.org\/10.7759\/cureus.65716","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7,30]]}}}